When the protein-processing machinery of the endoplasmic reticulum is overwhelmed by external stressors, it triggers a cascade of signaling pathways that culminate in programmed cell death. In the current landscape of 2026, oncology has moved decisively toward these types of organelle-specific
While the new therapy offers metabolic stability, researchers continue to monitor whether it can prevent long-term secondary complications such as kidney disease and liver tumors. The landscape of metabolic medicine is currently undergoing a profound transformation, moving away from simple symptom
In the fight against solid tumors, the structural optimization of cellular organelles may be the necessary step to keep frontline immune soldiers functional. Recent advancements in oncology have shifted focus toward the microscopic architecture of immune cells, particularly through the
Pharmaceutical experts believe that recalibrating potent immune-modulating drugs for chronic illness requires a deeper analysis of how these cells interact with a non-malignant immune system. This shift represents a significant pivot from the oncology-centric applications that defined early genomic
The engineering of autologous T-cells to express receptors for the Kappa Myeloma Antigen offers a precision-guided approach to treating the second most common blood cancer worldwide. This milestone has been realized through the commencement of the Phase 1 KOALA study, a first-in-human clinical
The SLICeVLP system decouples guide RNA delivery from Cas9 protein delivery to enable large-scale pooled CRISPR screening in primary human macrophages for the first time. This technological leap addresses a longstanding bottleneck in the field of immunotherapy, where the focus has historically
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42